CLINICAL TRIALS PROFILE FOR GANCICLOVIR SODIUM

All Clinical Trials for GANCICLOVIR SODIUM

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00002034 ↗	A Study of the Safety and Tolerance of Long-Term Therapy With Intravenous Cytovene (Ganciclovir Sodium) for Cytomegalovirus Retinitis in Persons With AIDS	Completed	Hoffmann-La Roche	N/A	1969-12-31	To evaluate the safety and tolerance of long-term ganciclovir (DHPG) therapy for newly diagnosed macular threatening Cytomegalovirus (CMV) retinitis in AIDS patients. To evaluate the clinical response to a 52 week course of intravenous DHPG therapy. To evaluate the safety and tolerance of long-term DHPG with concurrent treatment with zidovudine (AZT). (Patients utilizing treatment with other anti-retroviral drugs will be considered for study entry on a case by case basis.) To determine survival in this group of patients with AIDS and CMV retinitis.
NCT00986557 ↗	T-Lymphocyte Infusion or Standard Therapy in Treating Patients at Risk of Cytomegalovirus Infection After a Donor Stem Cell Transplant	Unknown status	University Hospital Birmingham	Phase 2	2009-09-01	RATIONALE: An infusion of cytomegalovirus-specific T lymphocytes may prevent or reduce cytomegalovirus infection during the first year after a donor stem cell transplant. PURPOSE: This randomized phase II trial is studying T-lymphocyte infusion to see how well it works compared with standard therapy in treating patients at risk of cytomegalovirus infection after a donor stem cell transplant.
NCT01199562 ↗	Infection Prophylaxis and Management in Treating Cytomegalovirus (CMV) Infection in Patients With Hematologic Malignancies Previously Treated With Donor Stem Cell Transplant	Completed	National Cancer Institute (NCI)		2010-12-01	RATIONALE: Infection prophylaxis and management may help prevent cytomegalovirus (CMV) infection caused by a stem cell transplant. PURPOSE:This clinical trial studies infection prophylaxis and management in treating cytomegalovirus infection in patients with hematologic malignancies previously treated with donor stem cell transplant.
NCT01199562 ↗	Infection Prophylaxis and Management in Treating Cytomegalovirus (CMV) Infection in Patients With Hematologic Malignancies Previously Treated With Donor Stem Cell Transplant	Completed	City of Hope Medical Center		2010-12-01	RATIONALE: Infection prophylaxis and management may help prevent cytomegalovirus (CMV) infection caused by a stem cell transplant. PURPOSE:This clinical trial studies infection prophylaxis and management in treating cytomegalovirus infection in patients with hematologic malignancies previously treated with donor stem cell transplant.
NCT03299452 ↗	Clinical Studies by Using Alphacait to Screen Drugs for Advanced Solid Tumor	Unknown status	Alphacait, LLC	Phase 2	2017-01-01	This is a single-center, open-label, single-arm, non-randomized study designed to evaluate PFS, safety, overall survival (OS), objective response rate (OPR), disease control rate (DCR) and biomarkers of cancer therapy based on Alphacait screening system in subjects with advanced malignant tumor.
NCT03299452 ↗	Clinical Studies by Using Alphacait to Screen Drugs for Advanced Solid Tumor	Unknown status	Haining Health-Coming Biotech Co., Ltd.	Phase 2	2017-01-01	This is a single-center, open-label, single-arm, non-randomized study designed to evaluate PFS, safety, overall survival (OS), objective response rate (OPR), disease control rate (DCR) and biomarkers of cancer therapy based on Alphacait screening system in subjects with advanced malignant tumor.
NCT03576898 ↗	Systemic and Topical Antivirals for Control of Cytomegalovirus Anterior Uveitis: Treatment Outcomes	Recruiting	Chulalongkorn University	Phase 2/Phase 3	2020-03-15	Cytomegalovirus (CMV) is generally a latent and asymptomatic infection in healthy, immunocompetent individuals. In immunocompromised patients CMV is well known to cause a retinitis that can lead to blindness. In immunocompetent patients, however, CMV can cause recurrent inflammation in the front of the eye (anterior uveitis). CMV anterior uveitis produces complications including pain, glaucoma, corneal failure, and vision loss. CMV anterior uveitis is commonly misdiagnosed as a non-infectious anterior uveitis and treated as such, which can beget further complications. Diagnosis requires directed polymerase chain reaction (PCR) testing. While antiviral therapy exists for CMV, identifying the appropriate therapy has been challenging because no randomized trials comparing routes of therapy (particularly oral or topical) have been performed. Oral antiviral therapy of CMV carries blood and kidney side effects that requires laboratory monitoring. Topical therapy has been reported to be effective, but no consensus as to the appropriate drug concentration exists. Here we propose a double-masked randomized controlled clinical trial comparing the efficacy of oral valganciclovir, topical ganciclovir 2%, and placebo for the treatment of PCR-proven CMV anterior uveitis. This pilot study will provide valuable information concerning the treatment of CMV anterior uveitis with oral and topical medications, including effective concentrations and side-effect profile. The information obtained from this study will help inform future larger clinical trials in CMV anterior uveitis.

Clinical Trial Conditions for GANCICLOVIR SODIUM

Condition Name

Condition Name for GANCICLOVIR SODIUM
Intervention	Trials
Cytomegalovirus Anterior Uveitis	2
Recurrent Marginal Zone Lymphoma	1
Contiguous Stage II Adult Immunoblastic Large Cell Lymphoma	1
Stage II Chronic Lymphocytic Leukemia	1

Condition MeSH

Condition MeSH for GANCICLOVIR SODIUM
Intervention	Trials
Cytomegalovirus Infections	3
Infection	2
Uveitis, Anterior	2
Uveitis	2

Clinical Trial Locations for GANCICLOVIR SODIUM

Trials by Country

Trials by Country for GANCICLOVIR SODIUM
Location	Trials
United States	10
China	2
Canada	1
United Kingdom	1

Trials by US State

Trials by US State for GANCICLOVIR SODIUM
Location	Trials
California	4
Texas	1
South Carolina	1
New York	1
Georgia	1

Clinical Trial Progress for GANCICLOVIR SODIUM

Clinical Trial Phase

Clinical Trial Phase for GANCICLOVIR SODIUM
Clinical Trial Phase	Trials
PHASE4	1
Phase 2/Phase 3	2
Phase 2	2

Clinical Trial Status

Clinical Trial Status for GANCICLOVIR SODIUM
Clinical Trial Phase	Trials
Recruiting	3
Unknown status	2
Completed	2

Clinical Trial Sponsors for GANCICLOVIR SODIUM

Sponsor Name

Sponsor Name for GANCICLOVIR SODIUM
Sponsor	Trials
Huang Pacific Foundation	2
Khon Kaen University	2
King Chulalongkorn Memorial Hospital	2

Sponsor Type

Sponsor Type for GANCICLOVIR SODIUM
Sponsor	Trials
Other	30
UNKNOWN	6
Industry	1

Ganciclovir Sodium: Clinical Trials Update, Market Analysis, and Projections

Last updated: May 2, 2026

What is the current clinical-trials position for ganciclovir sodium?

Ganciclovir sodium is an established antiviral used for herpesvirus infections, with clinical use dominated by legacy data and ongoing trials typically focused on new formulations, dosing strategies, combinations, and special populations rather than first-in-class mechanism claims.

Clinical trial activity (high level)

• Core indication set (dominant in real-world use): cytomegalovirus (CMV) retinitis in immunocompromised patients; congenital CMV; CMV prophylaxis and treatment in transplant and advanced immunosuppression settings.
• Trial pattern: studies tend to compare ganciclovir to alternatives (valganciclovir, foscarnet, cidofovir), test regimen changes, or evaluate delivery formats (oral conversion strategies, IV-to-oral transitions, population pharmacokinetics).

What matters for trial-facing decision-making

• Endpoints are usually virologic and safety-led: viral load reduction, time to viral clearance, incidence of CMV disease, relapse rates, and hematologic tolerability (neutropenia, anemia).
• Risk constraints are consistent: ganciclovir’s toxicity profile constrains dosing flexibility, so trial designs often emphasize exposure control rather than pure efficacy intensification.

Clinical development read-through (commercial relevance)

• In a mature antiviral category, development value usually comes from therapeutic differentiation via regimen optimization or platform delivery, not from mechanism novelty.
• For investors and partners, the practical lens is whether the program can shift standard-of-care toward lower cost per responder, improved adherence (if oral), or reduced toxicity burden.

Actionable conclusion: Clinical trial “update” for ganciclovir sodium tends to be incremental versus brand-new drug classes; the highest commercial leverage is typically in indication expansion, formulation, or competitive regimen positioning.

---

What does the market look like for ganciclovir sodium today?

Category context

Ganciclovir sits in the anti-CMV and herpesvirus antiviral market, where demand is driven by:

• immunosuppression cycles (especially transplant)
• ophthalmic CMV disease burden
• congenital CMV treatment guidelines (where antiviral therapy is used)
• local payer formularies and bundled care pathways

Competitive set (real spenders)

• Valganciclovir (oral prodrug of ganciclovir) is often the preferred oral option in standard pathways.
• Foscarnet and cidofovir compete in toxicity-limited or resistant scenarios.
• Newer CMV agents and monoclonal strategies exist in the broader landscape, but the commercial center of gravity in many geographies remains oral ganciclovir-family options plus rescue therapies.

Formulation and route economics

• IV ganciclovir supports inpatient/acute control or ophthalmic protocols.
• Oral valganciclovir often captures maintenance and outpatient demand due to convenience, which pressures direct ganciclovir sodium volume growth but does not eliminate IV demand for severe disease or special populations.

Demand durability

• The CMV disease base is persistent in transplant and immunocompromised populations.
• Patent and supply dynamics across generic producers can shape price corridors, but the patient population is relatively stable.

---

How should ganciclovir sodium be positioned commercially?

A practical market positioning framework for ganciclovir sodium is anchored on where IV use remains non-substitutable and where formulary access for sodium salt/generic supply matters.

Most defensible demand segments

• Severe CMV disease requiring IV induction
• Ocular CMV regimens and protocols where IV is used
• Patients unable to use oral dosing (absorption risk, intolerance, clinical instability)
• Setting-specific payer preferences where IV generics are contracted at favorable rates

Most realistic value propositions

• Reduced cost per treated patient via generic supply scale
• Lower regimen friction through optimized IV-to-oral transitions (even when valganciclovir is the oral endpoint, IV induction value persists)
• Improved safety management via dosing and monitoring protocols

---

What is the revenue outlook and forecast logic through 2030?

Forecasting approach that fits a mature generic

For mature antivirals with heavy generic penetration, forecasts are typically driven by:

• patient population stability (transplant throughput, immunosuppression prevalence)
• route mix (IV versus oral)
• pricing environment (generic erosion, tender dynamics)
• share retention (formulary inclusion, biosimilar-like substitution patterns, internal hospital protocols)

Scenario forecast (market-level, not company-specific)

Because ganciclovir sodium is widely available and price is sensitive to generic competition, projections are best expressed as range-based, pathway-driven outcomes rather than single-point growth claims.

Baseline scenario (most likely)

• Flat-to-low single-digit CAGR in value terms through 2030, driven by:
  • stable demand volumes
  • ongoing price pressure
  • limited route substitution impact (IV remains clinically anchored for a subset)

Bear scenario

• Low growth or declining value due to:
  • deeper tender price cuts
  • tighter substitution to valganciclovir
  • supply chain shifts toward fewer manufacturers in certain markets

Bull scenario

• Moderate value growth driven by:
  • expansion of guideline-driven antiviral use in specific subgroups
  • improved safety protocols that reduce discontinuations
  • regional formulary shifts favoring cost-effective IV therapy

Projection table (directional, pathway-driven)

Driver	Base case impact on value (2030)	Bear case	Bull case
Patient pool stability	Slight positive	Slight negative	Positive
IV-to-oral substitution	Neutral to slightly negative	Negative	Neutral
Generic pricing erosion	Negative	More negative	Less negative
Formulary access/tenders	Neutral	Negative	Positive
Safety management improvements	Slight positive	Neutral	Positive

Actionable conclusion: ganciclovir sodium is forecast to remain a durable, low-growth, high-supply-resilience product line, with competitive advantage tied to cost-per-course and supply reliability rather than novelty.

---

Where are the patent and regulatory constraints that matter most?

In many markets, ganciclovir sodium’s development economics are dominated by:

• generic approvals
• market access via tenders
• stability and supply continuity
• local labeling and guideline alignment

The specific patent estate varies by jurisdiction and by whether the relevant IP is formulation, manufacturing process, or use-specific. Commercially, the decisive factor is the degree of multi-source availability in key regions, which determines pricing floor and volatility.

---

Key risk map for pipeline and market-share execution

Clinical execution risks

• Hematologic toxicity limiting dose intensity
• Monitoring burden (ANC, hemoglobin, renal function)
• Patient adherence issues when regimens require transitions

Market and competitive risks

• Continuous pricing compression from multi-source generics
• Hospital formulary protocols that prefer oral valganciclovir
• Shift in CMV management patterns within immunosuppression programs

Supply chain risks

• API availability and manufacturing capacity concentration
• Regulatory inspection outcomes affecting supply continuity

---

Key Takeaways

1. Clinical activity for ganciclovir sodium is typically incremental and centered on regimen optimization, special populations, and combination or transition strategies rather than mechanism breakthroughs.
2. Market demand is stable but monetization is constrained by strong generic competition and route substitution pressure from valganciclovir.
3. Forecasts through 2030 trend toward flat-to-low single-digit value growth under baseline conditions, with outcomes primarily determined by IV versus oral mix, tender pricing, and formulary access.
4. Commercial edge is execution-focused: cost-per-course, supply reliability, and safety-managed treatment pathways.

---

FAQs

1) Is ganciclovir sodium still used when valganciclovir exists?

Yes. IV ganciclovir remains relevant for severe CMV disease, ocular regimens, and patients who cannot use oral therapy reliably.

2) What endpoints drive clinical success for ganciclovir sodium trials?

Virologic response (viral load reduction/clearance) plus safety and time-to-clinical improvement, with hematologic toxicity monitoring central to trial outcomes.

3) Why does market value growth lag even if patient demand persists?

Generic price erosion and formulary substitution toward oral valganciclovir typically cap revenue growth.

4) What is the most important commercial lever for ganciclovir sodium suppliers?

Tender pricing and supply continuity, because multi-source competition dominates.

5) What scenario best describes 2030 outlook?

Baseline expectations point to stable demand with low single-digit value growth, with bear risks tied to deeper price compression and bull upside tied to guideline or formulary shifts that sustain IV use.

---

References

[1] ClinicalTrials.gov. “Ganciclovir” (search results and trial listings). U.S. National Library of Medicine. https://clinicaltrials.gov/
[2] U.S. Food and Drug Administration. “Cytovene (ganciclovir) / prescribing information and related regulatory materials.” https://www.fda.gov/
[3] National Comprehensive Cancer Network (NCCN). “Guidelines for Cancer- and Transplant-Related CMV Management” (CMV screening and treatment recommendations). https://www.nccn.org/
[4] EMA. “Cytovene (ganciclovir) and related assessment documentation” (where available in the EMA database). https://www.ema.europa.eu/